Applied Therapeutics IncNASDAQ:APLT
- LAST PRICE4.5500
- TODAY'S CHANGE (%)0.1000 (2.2472%)
- Bid / Lots4.4000/ 5
- Ask / Lots4.8400/ 1
- Open / Previous Close4.5200 / 4.4500
- Day Range
- 52 Week Range
- Volume2,781,897
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APLT |
|---|---|---|
| 09:32 ET | 8848 | 4.52 |
| 09:34 ET | 1378 | 4.549 |
| 09:36 ET | 627 | 4.5 |
| 09:39 ET | 100 | 4.53 |
| 09:41 ET | 782 | 4.55 |
| 09:43 ET | 546 | 4.58 |
| 09:45 ET | 1000 | 4.535 |
| 09:48 ET | 100 | 4.535 |
| 09:50 ET | 1500 | 4.6 |
| 09:52 ET | 220 | 4.59 |
| 09:54 ET | 1774 | 4.52 |
| 09:56 ET | 756 | 4.47 |
| 09:57 ET | 3604 | 4.47 |
| 09:59 ET | 700 | 4.54 |
| 10:01 ET | 400 | 4.47 |
| 10:03 ET | 1790 | 4.5099 |
| 10:06 ET | 400 | 4.51 |
| 10:08 ET | 900 | 4.52 |
| 10:12 ET | 713 | 4.53 |
| 10:14 ET | 300 | 4.55 |
| 10:17 ET | 330 | 4.51 |
| 10:19 ET | 500 | 4.51 |
| 10:21 ET | 100 | 4.54 |
| 10:24 ET | 148 | 4.53 |
| 10:26 ET | 400 | 4.54 |
| 10:28 ET | 500 | 4.54 |
| 10:30 ET | 1254 | 4.53 |
| 10:32 ET | 1264 | 4.524 |
| 10:33 ET | 200 | 4.525 |
| 10:35 ET | 806 | 4.51 |
| 10:39 ET | 1200 | 4.5178 |
| 10:42 ET | 1608 | 4.52 |
| 10:46 ET | 200 | 4.5113 |
| 10:48 ET | 300 | 4.53 |
| 10:50 ET | 513 | 4.53 |
| 10:53 ET | 1356 | 4.54 |
| 10:55 ET | 300 | 4.52 |
| 10:57 ET | 100 | 4.51 |
| 11:00 ET | 100 | 4.49 |
| 11:02 ET | 200 | 4.49 |
| 11:06 ET | 100 | 4.505 |
| 11:08 ET | 100 | 4.51 |
| 11:09 ET | 224 | 4.52 |
| 11:11 ET | 1451 | 4.48 |
| 11:13 ET | 241 | 4.47 |
| 11:15 ET | 700 | 4.49 |
| 11:18 ET | 300 | 4.5 |
| 11:20 ET | 400 | 4.495 |
| 11:24 ET | 300 | 4.5 |
| 11:29 ET | 100 | 4.49 |
| 11:31 ET | 1100 | 4.4915 |
| 11:33 ET | 300 | 4.49 |
| 11:36 ET | 100 | 4.49 |
| 11:38 ET | 500 | 4.48 |
| 11:40 ET | 700 | 4.48 |
| 11:42 ET | 200 | 4.48 |
| 11:44 ET | 975 | 4.465 |
| 11:45 ET | 300 | 4.465 |
| 11:47 ET | 100 | 4.47 |
| 11:51 ET | 511 | 4.469 |
| 11:54 ET | 400 | 4.46 |
| 11:56 ET | 1300 | 4.465 |
| 11:58 ET | 1165 | 4.475 |
| 12:00 ET | 100 | 4.475 |
| 12:02 ET | 100 | 4.475 |
| 12:03 ET | 600 | 4.48 |
| 12:05 ET | 200 | 4.475 |
| 12:07 ET | 2420 | 4.465 |
| 12:09 ET | 709 | 4.48 |
| 12:12 ET | 200 | 4.47 |
| 12:14 ET | 333 | 4.475 |
| 12:16 ET | 400 | 4.475 |
| 12:18 ET | 1133 | 4.47 |
| 12:20 ET | 100 | 4.47 |
| 12:21 ET | 100 | 4.47 |
| 12:23 ET | 400 | 4.47 |
| 12:25 ET | 833 | 4.4626 |
| 12:27 ET | 100 | 4.465 |
| 12:30 ET | 1100 | 4.475 |
| 12:34 ET | 200 | 4.475 |
| 12:36 ET | 300 | 4.475 |
| 12:38 ET | 500 | 4.4767 |
| 12:39 ET | 1860 | 4.455 |
| 12:41 ET | 300 | 4.45 |
| 12:43 ET | 500 | 4.455 |
| 12:45 ET | 1533 | 4.465 |
| 12:48 ET | 100 | 4.465 |
| 12:50 ET | 1299 | 4.46 |
| 12:52 ET | 100 | 4.46 |
| 12:54 ET | 400 | 4.465 |
| 12:56 ET | 300 | 4.465 |
| 12:57 ET | 500 | 4.465 |
| 12:59 ET | 400 | 4.47 |
| 01:01 ET | 1866 | 4.464 |
| 01:03 ET | 788 | 4.46 |
| 01:06 ET | 2021 | 4.46 |
| 01:10 ET | 200 | 4.465 |
| 01:12 ET | 800 | 4.46 |
| 01:14 ET | 200 | 4.47 |
| 01:15 ET | 200 | 4.465 |
| 01:17 ET | 100 | 4.465 |
| 01:19 ET | 5440 | 4.49 |
| 01:21 ET | 100 | 4.485 |
| 01:24 ET | 1137 | 4.475 |
| 01:26 ET | 1200 | 4.47 |
| 01:28 ET | 628 | 4.47 |
| 01:30 ET | 3060 | 4.46 |
| 01:32 ET | 100 | 4.465 |
| 01:33 ET | 200 | 4.465 |
| 01:35 ET | 300 | 4.46 |
| 01:37 ET | 200 | 4.46 |
| 01:39 ET | 300 | 4.46 |
| 01:42 ET | 693 | 4.46 |
| 01:44 ET | 1409 | 4.47 |
| 01:46 ET | 100 | 4.46 |
| 01:48 ET | 500 | 4.47 |
| 01:50 ET | 100 | 4.47 |
| 01:51 ET | 1100 | 4.485 |
| 01:53 ET | 925 | 4.47 |
| 01:55 ET | 680 | 4.465 |
| 01:57 ET | 100 | 4.46 |
| 02:00 ET | 600 | 4.45 |
| 02:02 ET | 200 | 4.45 |
| 02:04 ET | 800 | 4.45 |
| 02:06 ET | 100 | 4.45 |
| 02:08 ET | 500 | 4.455 |
| 02:09 ET | 200 | 4.45 |
| 02:11 ET | 400 | 4.45 |
| 02:13 ET | 200 | 4.455 |
| 02:15 ET | 100 | 4.455 |
| 02:18 ET | 1414 | 4.465 |
| 02:20 ET | 1121 | 4.46 |
| 02:22 ET | 200 | 4.46 |
| 02:24 ET | 200 | 4.46 |
| 02:26 ET | 1937 | 4.46 |
| 02:27 ET | 1300 | 4.46 |
| 02:29 ET | 400 | 4.45 |
| 02:31 ET | 989 | 4.465 |
| 02:33 ET | 300 | 4.465 |
| 02:36 ET | 1351 | 4.475 |
| 02:38 ET | 818 | 4.475 |
| 02:40 ET | 1903 | 4.49 |
| 02:42 ET | 1203 | 4.49 |
| 02:44 ET | 966 | 4.485 |
| 02:45 ET | 917 | 4.485 |
| 02:47 ET | 1180 | 4.485 |
| 02:49 ET | 2204 | 4.49 |
| 02:51 ET | 703 | 4.495 |
| 02:54 ET | 1358 | 4.5 |
| 02:56 ET | 3748 | 4.475 |
| 02:58 ET | 900 | 4.47 |
| 03:00 ET | 6558 | 4.46 |
| 03:02 ET | 1001 | 4.46 |
| 03:03 ET | 667 | 4.46 |
| 03:05 ET | 1094 | 4.45 |
| 03:07 ET | 600 | 4.45 |
| 03:09 ET | 1176 | 4.465 |
| 03:12 ET | 1223 | 4.465 |
| 03:14 ET | 678 | 4.47 |
| 03:16 ET | 3381 | 4.47 |
| 03:18 ET | 1028 | 4.47 |
| 03:20 ET | 2115 | 4.475 |
| 03:21 ET | 829 | 4.475 |
| 03:23 ET | 1631 | 4.49 |
| 03:25 ET | 7766 | 4.495 |
| 03:27 ET | 1000 | 4.5 |
| 03:30 ET | 5551 | 4.49 |
| 03:32 ET | 1970 | 4.495 |
| 03:34 ET | 630 | 4.5 |
| 03:36 ET | 1239 | 4.495 |
| 03:38 ET | 1109 | 4.495 |
| 03:39 ET | 2943 | 4.485 |
| 03:41 ET | 3078 | 4.495 |
| 03:43 ET | 4868 | 4.5 |
| 03:45 ET | 3348 | 4.51 |
| 03:48 ET | 5209 | 4.485 |
| 03:50 ET | 3752 | 4.49 |
| 03:52 ET | 42508 | 4.55 |
| 03:54 ET | 11251 | 4.56 |
| 03:56 ET | 17070 | 4.53 |
| 03:57 ET | 24685 | 4.545 |
| 03:59 ET | 22765 | 4.55 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Applied Therapeutics Inc | 508.5M | -2.4x | --- |
Iteos Therapeutics Inc | 532.5M | -3.9x | --- |
Taysha Gene Therapies Inc | 516.2M | -2.5x | --- |
Allogene Therapeutics Inc | 508.5M | -1.4x | --- |
Third Harmonic Bio Inc | 505.3M | -16.6x | --- |
Savara Inc | 514.1M | -10.1x | --- |
Company Information
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Contact Information
- Headquarters
- 545 FIFTH AVENUE, SUITE 1400NEW YORK, NY, United States 10017
- Phone
- 212-220-9226
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Founder
- Shoshana Shendelman
- Chief Financial Officer and Principal Financial Officer, Director
- Leslie Funtleyder
- Chief Operating Officer and Chief Business Officer
- Constantine Chinoporos
- Interim Principal Financial Officer, Chief Accounting Officer
- Catherine Thorpe
- Chief Commercial Officer
- Dale Hooks
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $508.5M |
|---|---|
Revenue (TTM) | $-477.0K |
Shares Outstanding | 114.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.98 |
EPS | $-1.91 |
Book Value | $-0.20 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
